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Abstract: Clinical intervention studies support the efficacy and safety of exercise programs as a
treatment modality for non-small-cell lung cancer (NSCLC) during adjuvant/palliative treatment,
but the effectiveness of real-world oncogeriatric services is yet to be established. We aimed to
examine the effects of a 10-week structured and individualized multicomponent exercise program on
physical/cognitive functioning and mental wellness in elderly patients with NSCLC under adjuvant
therapy or palliative treatment. A non-randomized, opportunistic control, longitudinal-design trial
was conducted on 26 patients with NSCLC stage I–IV. Of 34 eligible participants, 21 were allocated into
two groups: (i) control group (n = 7) received usual medical care; and (ii) intervention group (n =19)
received multicomponent program sessions, including endurance, strength, balance, coordination and
stretching exercises. Tests included the Short Physical Performance Battery (SPPB), 5-m habitual Gait
Velocity Test (GVT), Timed Up & Go Test (TUG), 6-Min Walk Test (6MWT), independence of activities
in daily living (IADL), muscular performance, cognitive function, and quality of life, which were
measured at baseline and after 10 weeks of the program. Results revealed a significant group×time
interaction for SPPB (p = 0.004), 5-m GVT (p = 0.036), TUG (p = 0.007), and muscular performance
(chest and leg power; p < 0.001). Similarly, significant changes were observed between groups for
cognitive functioning (p = 0.021) and quality of life for EUROQoL 5D (p = 0.006). Our findings confirm
that a multicomponent exercise program improves measures of physical/cognitive functioning and
quality of life in the elderly with NSCLC under adjuvant therapy or palliative treatment. This is an
interesting and important study that adds to our current body of knowledge on the safety of exercise
interventions, especially in the elderly with solid tumors.
Keywords: exercise therapy; physical function; strength; functional capacity; lung cancer; elderly
1. Introduction
Lung cancer remains a leading cause of mortality worldwide among men and women,
with 2.1 million new lung cancer cases and 1.8 million deaths predicted in 2018, representing
almost 1 in 5 cancer deaths (18.4%) [1]. Lung cancer is the second most prevalent type of cancer and is
broadly divided into two categories based on histological characteristics: small cell lung cancer (SCLC,
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representing 20–25% of all diagnosed lung cancer cases) and non-small-cell lung cancer (NSCLC,
70–85% of cases) [2]. The most important risk factor for lung cancer is tobacco smoking, although
other causes include environmental pollutants [3]. The probability of developing lung cancer increases
considerably as patients age, accounting for ~60% of all new cases according to the International
Agency for Research on Cancer GLOBOCAN 2012 project [1]. The majority of patients with lung cancer
(~75%) have incurable locally advanced or metastatic cancers at the time of diagnosis and have a mean
five-year mortality rate of 85–90% [4].
Cancer is primarily a disease of the elderly. Elderly patients with NSCLC experience a complex
set of symptoms such as dyspnea, fatigue, shortness of breath, weight loss and pain, as well as distress
caused by anticancer treatment, the disease itself, and psychological distress in the form of resignation,
anxiety, and/or depression [5]. In developed countries, people aged 75 and over already represent
around one third of cancer patients, and incidence rates are increasing with age for most tumors [4–6].
All of these features have a likely effect on physical function/performance and will have a negative
impact on health-related quality of life (HRQoL), functional status, and the ability to participate in
activities of daily living (ADLs) [6]. Thus, improving psychosocial well-being to enhance HRQoL and
physical function is a primary goal at all stages of lung cancer during treatment and survivorship [7].
Adjuvant therapy (additional cancer treatment) may include chemotherapy, radiation therapy,
hormone therapy, targeted therapy, or biological therapy. In addition, the therapeutic options for
advanced NSCLC are based on numerous factors including histological characteristics, stage of
the disease, and the patient’s performance status [8], and can involve different strategies such as:
(i) minimal invasive surgery by video-assisted thoracoscopic surgery (VATS); (ii) chemotherapy,
chemoradiotherapy, immunotherapy (neoadjuvant), targeted therapy, either in combination or in
isolation; (iii) palliative care; (iv) comprehensive rehabilitation program; (v) physical exercise [9].
However, these options are limited in many cases because of poor functional status including older
age, comorbidities, sedentary behavior, poor exercise capacity, and loss of muscle strength.
Strategies that complement advances in conventional cancer treatment, especially those that
reduce treatment-related morbidities, are of major clinical importance in the oncogeriatric population.
This could be because reduced functional ability in many elderly is a result of critical deterioration of a
complexity of function, for example, balance, endurance, muscle strength, coordination, and reaction
capacity [7,9]. It is therefore likely that a supervised exercise program with the aim of improving these
functions would be required in order to improve the ability to perform basic daily tasks in general.
However, many studies have focused on the impact of intensive single-component training on isolated
functions in laboratory settings [10–12].
Recent years have witnessed a growing interest in non-invasive interventions for patients with
lung cancer, with the goal of maximizing exercise performance capacity and other outcomes such
as muscle strength and HRQoL, and decreasing emotional distress [10]. Recently, multicomponent
exercise programs have been demonstrated to be safe and well tolerated, but there remains a paucity of
data to draw conclusive and precise exercise guidelines [11,12]. For example, a recent Cochrane review
of six randomized controlled trials (n = 221) failed to establish any conclusive evidence regarding
efficiency of exercise training on physical fitness and other outcomes such as cardiorespiratory
capacity, muscle strength, mental wellness, and HRQoL in patients with advanced lung cancer [12].
Thus, the effectiveness of multicomponent exercise programs on these outcomes in these patients is
unclear [13]. Likewise, the effectiveness of exercise training in improving other outcomes, such as
physical functioning, cognitive functioning, and mental wellness is yet to be demonstrated.
Therefore, the objective of this research was to examine the effects of a 10-week structured
and individualized multicomponent exercise program on physical/cognitive functioning and mental
wellness in elderly patients with NSCLC under adjuvant therapy or palliative treatment. Accordingly,
the research question for this intervention study was: does a structured and individualized
multicomponent exercise program improve physical/cognitive functioning and HRQoL outcomes
more than usual care among the elderly with NSCLC?
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2. Methods
2.1. Study Design, Setting and Ethical Considerations
This was a non-randomized, opportunistic control, longitudinal trial designed to examine the
effects of a multicomponent exercise program on surrogate measures of health status in patients with
lung cancer in real-world settings. Patients were treated at the Oncogeriatrics Unit of the Complejo
Hospitalario de Navarra (CHN). The study ran from May 2018 to November 2019 and was approved
by the CHN Research Ethics Committee (25, April, 2018, reference number Pyto2018/5#214) according
to the principles of the World Medical Association Declaration of Helsinki. Verbal explanations of
the aims and intervention of the study were provided to the patients, and those who were willing to
participate signed a written informed consent form.
2.2. Patient Population
We enrolled newly diagnosed patients with NSCLC stage I–IV (Tumour, node, metastasis (TNM)
classification) [14], histologically confirmed at CHN hospital and approached consecutively, advised
about the study, screened for eligibility (if willing) and invited to participate in the study (if eligible)
by physicians for curative or palliative purposes. The study included an initial exam at the first visit
(baseline) and a final exam after 10-weeks. A trained research assistant conducted a screening interview
to determine whether potentially eligible patients met the following inclusion criteria: aged 70 years
or older; have a diagnosis of confirmed lung cancer; with life expectancy exceeding three months
(prognosis); with multimorbidity, presence of geriatric syndromes or fragility (VES13/ G8 Index); Barthel
score ≥60 points; and able to communicate and collaborate with the research team. Exclusion criteria
were: clinically unstable patients defined medically as having received active treatment (chemotherapy
or radiotherapy) for the neoplasm before inclusion in the study; moderate-severe cognitive impairment
considered as a score ≥5 in the Reisberg Global Deterioration Scale; and contraindications to exercise,
or already engaged in high levels of physical training. All testing procedures were carried out at the
biomedical research center of the Government of Navarre (Navarrabiomed) and CHN, Universidad
Pública de Navarra, Pamplona, Spain. Participants received no monetary incentive. The trial protocol
was developed according to the Standardized Protocol Items: Guidelines for reporting non-randomized
studies [15]. Due to the nature of the intervention, participants and researchers were not blinded;
however, the principal investigator was not involved in the exercise training and analyses were
performed blinded for group allocation. Each participant was assessed in the same period of the day
(morning or afternoon) in a metabolic and sport science research laboratory by the same assessor.
2.3. Outcome Assessment
After enrollment, patients were invited to visit Navarrabiomed Lab to collect baseline data.
The baseline data included anthropometry (weight and height), prognosis, health status, polypharmacy,
geriatric syndromes or fragility status, cognitive impairment, clinically diagnosed comorbidities, tumor
node metastasis classification, adjuvant therapy/palliative treatment, and dependence. Height was
measured to the nearest 0.1 cm using a stadiometer and body weight to the nearest 0.1 kg using digital
scales. Body mass index (BMI) was also calculated.
The primary outcome was objectively measured physical functioning using the “Short Physical
Performance Battery” (SPPB) [16]. To assess usual walking speed (meters/second), the participants
were asked to walk 4 m at their regular pace twice from a standing position. The standing balance tests
included side-by-side, semi-tandem, and full-tandem standing, and the participants were timed until
they moved, or 10 s had elapsed. To assess the 5-times sit-to-stand test, the participants were asked to
perform five chair stands as quickly as possible. Time (in seconds) was registered with a stopwatch
with a resolution of 0.01 s. The total score ranged from 0 (worst) to 12 points (best). An increase of
1-point is recommended in disability research [16]. In this context, quantifying physical performance
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status after cancer treatment may provide important insights to clinicians on the health, vitality, and
prognosis of cancer survivors [17].
The secondary outcomes were physical functioning by: (i) 5-m habitual gait velocity test (GVT);
(ii) timed up and down stairs test (TUDs); (iii) 6-min walk test (6MWT); (iv) dependence; (v) muscular
performance; (vi) cognitive functioning; (vii) mental wellness, which are commonly used measurements
of functional/exercise capacity in patients with pulmonary morbidity or cancer [13]. For the GVT,
participants were instructed to walk at their usual pace. All clinical outcome measures (minimum
clinical difference or validity test) included in this study has been previously reported in similar
population and real-world settings [13,17–32]. Dual-task conditions (gait evaluation during the
simultaneous performance of a cognitive task) have recently been recognized as a sensitive assessment
method for interactions among cognition, gait, falls, and frailty [18]. Two trials were conducted to
assess gait velocity while the patient performed a verbal or counting task (verbal GVT and arithmetic
GVT, respectively). During the verbal dual-task condition (verbal GVT), the gait speed was measured
while the participants named animals aloud. During the arithmetic dual-task condition (arithmetic
GVT), the gait speed was evaluated while the participants counted backwards aloud from 100 in ones.
After the familiarization sessions, the following tests validated for this population were performed:
TUG: rom a starting position with the hips, knees, and ankles flexed at 90◦, the participants had to rise
from a chair, with no armrests, walk 3 m, return, and sit back in the chair. Participants were instructed not
to run. The 6MWT was used as a measure of physical function in older adults [19]. Briefly, patients were
instructed to walk as far as possible along a short-measured course during 6 min in a 30-m field [20].
The time in all of the tests was measured by the same evaluator and with the same chronometer to the
nearest 0.1s. Dependence was assessed with an ADLs evaluation using a Spanish-adapted version of
the physical level activities of daily living (Barthel score), recommended for epidemiological studies
in the elderly [21]. The items of the Barthel Index are weighted: a maximum score of 100 indicates
independence, 91–99 minimal dependence, 75–90 mild dependence, 50–74 moderate dependence,
25–49 severe dependence, and 0–24 total dependence [22].
Used widely in studies of patients with cancer, muscle strength was measured by the maximal
amount of weight that each muscle group (lower extremity (leg press) and upper extremity (chest
press) can move through the available range of motion (1 repetition maximum (1RM)) using eGym®
equipment (eGym® GmbH, München, Germany)). Maximal strength was assessed by a handgrip
test (Jamar, Sammons Preston Rolyan, Nottinghamshire, UK), whereas knee extension, flexion, and
abduction hip were determined using a digital dynamometer (Hoggan Scientific LLC, Salt Lake
City, UT; Micro FET 2 muscle testing). Two trials were performed and the average was used for
subsequent analyses.
Cognitive functioning was assessed by several tests. The mini-mental state examination (MMSE)
assesses domains of orientation, memory, attention, language, and visuospatial ability, with a maximum
score of 30 points [23]. Scores ≤23 points are indicative of likely cognitive impairment. In the verbal
fluency test, the patient had 1 min to enumerate as many words as possible starting with the letter F [24].
The Trail Making Test, part A (TMT-A) is an indicator of visual scanning, graphomotor speed, and
executive function. In this case, patients were asked to connect randomly arranged circles containing
numbers from 1 to 25 following the number sequence as quickly as possible [25].
Self-perceived physical function and health status were evaluated using the HRQoL and questions
on cancer-related symptoms. These questionnaires included the European Quality of Life-5 Dimensions
(EUROQoL 5D) and the “European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire” (EORTC QLQ) [26]. This last instrument combined the general part (QLQ-C30)
and the lung-specific part (QLQ-LC13). The reliability and validity of the EORTC QLQ-C30/LC13 has
been reported for exclusive use in patients with lung cancer [27]. It is composed of both multi-item
scales and single-item measures that contain five independently functional subscales (physical, role,
cognitive, emotional, and social); three symptom subscales (fatigue, pain, and nausea and vomiting);
and a global health/QoL subscale. Furthermore, it comprises six single items assessing symptoms
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commonly reported by cancer patients (dyspnea, appetite loss, sleep disturbance, constipation, and
diarrhea). This test establishes an intuitive association between categories and a numerical equivalent,
such as 0-Nothing, 4-Little, 6-Some, 10-Much [28]. A short version of the Geriatric Depression Scale
(GDS) [29] developed in 1986, was used, and included 15 relevant questions selected from a longer
GDS version regarding the highest correlation with depressive symptoms in validation studies.
Scores of 0–4 are considered normal, according to age, education, and complaints; 5–8 indicates mild
depression; 9–11 indicates moderate depression; and 12–15 indicates severe depression [30]. Finally,
Borg’s perceived exertion scale was used, which measures the extent of perceived exertion that a person
experiences during exercise [31]. Physical and mental outcomes were tested by a highly qualified
Master of science-level physiotherapist with 15 years of experience.
Members of the research team were able to access the medical records of each patient, which
contained important data such as tumor node metastasis classification, frailty status (G8 and VES 13),
alcohol and smoking status (current, past or no), surgery type (VATS, open, without surgery), and
adjuvant therapy/palliative treatment (chemotherapy, immunotherapy, radiotherapy, immunotherapy
and palliative treatment). The same assessments were repeated at 8- and 10-weeks after intervention
or usual care. All outcomes were collected at Navarrabiomed via face-to-face interviews by trained
health workers.
2.4. Intervention
Usual nursing and medical care were provided to all participants in all groups. The control group
(CG) included participants who were not referred to the Oncogeriatrics services or who were on an
extended waiting list for oncology treatment and were willing to undergo an assessment of physical
function and clinical status at baseline and after 10 weeks. These participants had not practiced any
kind of supervised physical exercises/activities during the intervention 10-weeks, but received normal
outpatient care, including physical rehabilitation when needed.
The intervention group (IG) receiving the multicomponent exercise program was carried out
in the Navarrabiomed Lab facilities. In this line, the most beneficial type of physical exercise is
called multicomponent exercise, according to feasibility and safe intervention from our lung cancer
study. [13,18,32]. It is recommended that the multicomponent exercise program is individualized
according to treatment of the cancer patient and their general health condition. This type of program
combines strength (resistance), endurance (aerobic), balance/coordination, and flexibility training and
has been shown to result in great improvements in functional capacity, which is a key point in maintaining
independence in instrumental and basic activities of daily living. Each session lasted 45–50 min and
the exercise protocol was performed twice a week over 10 weeks. Attendance was registered by the
patients at every exercise session in an exercise diary logbook kept at the Navarrabiomed Lab Centre.
Adherence to the exercise intensity was monitored by HR monitor (Polar Team, A2 Polar Electro
Oy, Kempele, Finland). A highly qualified physiotherapist (I.D.-R.) supervised each training session.
The exercise program was individualized and included measurements of vital signs at the beginning and
end of each session (oxygen saturation-SpO2, heart rate-HR, blood pressure-BP). The program contained
endurance exercise, such as classic recumbent exercise bike (R20 Vision Fitness Comfort Arc™, Taichung,
Taiwan,) 50–80% of HR, squeezing a ball (3–5 min); getting up from a chair (3 sets/10 repetitions); balance
and coordination (2 sets); eGym® machines (Model M5 and M9 eGym equipment ® Berlín Germany),
maximum strength in chest press (1RM), power chest (3 sets/12 repetitions at 30% of 1RM), maximum
strength in leg press (1RM), and power legs (3 sets/12 repetitions at 30% of 1RM); hip abduction with
elastic bands (3 sets/10 repetitions); and general stretching exercises (5 min). The amount of chest and leg
press ranged from 30% to 60% of 1RM and 8–12 repetitions according to the training week. The external
load was adjusted weekly to maintain the % of the 1RM (from 30% to 60% of 1RM) and total number
of repetitions per exercise (8 to 12 repetitions). The intensity of the exercises increased individually
and progressively according to the patient’s response, pain, dyspnea, and feelings of well-being or
fatigue on each day of exercise. Additionally, assistance was provided to subjects during the exercise to
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complete the proposed RM. Patients were advised to carry out the “Vivifrail” [32] program at home
during the entire study period. The program is personalized, depending on the older person’s functional
capacity level (serious limitation, moderate limitation, and slight limitation as evaluated by the SPPB,
and a walking speed test) and the risk of falling [32]. This type of intervention has also been proven
as the most effective to delay disability, cognitive impairment, and depression as well as effective in
reversing the functional decline associated with acute hospitalization in very old patients, (Table 1) [32].
The multicomponent exercise protocol and “Vivifrail” [32] program comply with the American College
of Sports Medicine exercise guidelines for cancer in relation to improving physical fitness and restoring
physical functioning, enhancing quality of life, and mitigating cancer-related fatigue [18].
Table 1. Multi-component exercise program.
n Exercise Frequency Duration Intensity
1. Endurance exercise: riding a bicycle Twice a week 3–5 min 50–80% of HR max
2. Get up from a chair Twice a week 3 sets × 10 repetitions −
3.
Balance and coordination
Walking on toes with flexion-extension
shoulder
Walking on heels of the feet with
abduction-adduction shoulder
Progression with obstacles along the way
Twice a week 2 sets × 5 m −
4. Maximum strength/power in chest press(eGym®) Twice a week 2 times (for control load) 1RM
5. Maximum strength/power in leg press(eGym®) Twice a week 2 times (for control load) 1RM
6. Power chest (Explosive program eGym®) Twice a week
Week 1
3 sets/12 repetitions 30% RM
Week 2–3
3 sets/12 repetitions 40% RM
Week 4–7
3 sets/10 repetitions 50% RM
Week 8–10
3 sets/8 repetitions 60% RM
7. Power legs (Explosive program eGym®) Twice a week
Week 1
3 sets/12 repetitions 30% RM
Week 2–3
3 sets/12 repetitions 40% RM
Week 4–7
3 sets/10 repetitions 50% RM
Week 8–10
3 sets/8 repetitions 60% RM
8. Hip abduction with elastic bands(TheraBand) Twice a week 3 sets/10 repetitions
50–80% band
elongation
(red-black)
9. Squeezing a ball Twice a week 3 sets/3–5 min −
10. General stretching exercises (6–10exercises) Twice a week 5 min −
Abbreviations: HR: Heart Rate; RM: Repetition Maximum.
2.5. Statistical Analyses
All analyses were performed by a researcher who was not involved in the study participants’
assessments and interventions. The statistical data analysis was performed with the commercial
software SPSS Statistics version 25.0 (IBM Corp., Chicago, IL). The Shapiro-Wilk test was used to
determine whether parametric tests were appropriate. Normality of data was checked graphically.
In the present study, descriptive data, including frequencies for categorical variables and means
standard deviation (SD) for continuous variables, were reported. Baseline differences were analysed
using chi squared (X2) test for nominal data and the Kruskal–Wallis test for ordinal data. The change
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value was calculated post-pre (∆) with 95% confidence intervals (95%CI), to compare differences
between the groups. Non-parametrical data were analyzed with the Wilcoxon and Mann-Whitney U
tests. For parametric data, Student’s t tests were used. A significance level of 5% (p < 0.05) was adopted
for all statistical analyses.
3. Results
3.1. Characteristics of Participants
Of the 42 volunteers, 34 attended the oncologic and geriatric clinics screening. Of these,
26 completed the 10-weeks intervention. Two patients from the IG did not complete the program
due to death or esophageal surgery. Data from the 19 remaining patients from the IG were analyzed.
A total of 6 of the 13 CG subjects dropped out of the study and did not take the final exam due to the
progression of the disease (three) or death (three). Data from the seven remaining CG participants
were analyzed. A total of 19 participants (4 females, 15 males) were eligible for analysis in the IG and
7 participants (2 females, 5 males) in the CG (Figure 1). All subjects in the IG completed at least 86% of
the planned training sessions. No major adverse events or health-related issues attributable to the
testing or training sessions were noted.
Table 2 displays the baseline characteristics by group. No significant differences were found
between the two groups, except for age. Patients in the IG had a mean (SD) age of 74.5 (3.6) years, in
the range 70–81 years (78.9% males), and BMI 26.8 (4.5) kg/m2. In total, 41.2% underwent surgery and
78.9% received adjuvant chemotherapy alone or in combination with other therapies. Participants in
the CG had a mean (SD) age of 79.0 (3.0) years, in the range 75–83 years (71.4% males), and BMI 25.5
(2.5) kg/m2. Within this group, 14% were submitted to surgery and 85.7% were receiving adjuvant
chemotherapy alone or in combination with other therapies.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 17 
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Table 2. Baseline characteristics of the participants.
Variables Intervention Group(n = 19)
Control Group
(n = 7) p-Value
Age 74.5 (3.6) 79.0 (3.0) 0.007 *
BMI, kg/m2 26.8 (4.5) 25.5 (2.5) 0.491 *
Underweight, n (%) 5 (26.3) 1 (14.3)
0.912 †Normal weight, n (%) 7 (36.8) 4 (57.1)
Overweight/obesity, n (%) 7 (36.8) 2 (28.6)
Sex, n (%)
Male
Female
15 (78.9)
4 (21.1)
5 (71.4)
2 (28.6) 0.700 +
TNM classification, n (%)
I
II
IIIa-IIIb-IIIc
IV
1 (5.3)
0 (0.0)
4 (21.0)
14(73.7)
0 (0.0)
1 (14.3)
3 (42.8)
3 (42.8)
0.172 †
Clinically diagnosed comorbidities,
n (%)
0.496 +
COPD 13 (68.4) 2 (28.6)
Hypertension 9 (47.4) 4 (57.1)
Diabetes mellitus 5 (26.3) 1 (14.3)
Cardiovascular diseases 8 (42.1) 4 (57.1)
Frailty status, n (%)
G8
VES 13
G8 and VES13
No
7 (36.8)
2 (10.5)
4 (21.1)
6 (31.6)
3 (42.8)
0 (0.0)
3 (42.8)
1 (14.3)
0.649 +
Alcohol status, n (%)
Current
Past
No
10 (52.6)
4 (21.1)
5 (26.3)
2 (28.6)
3 (42.8)
2 (28.6)
0.407 +
Smoking status, n (%)
Current
Past
No
5 (26.3)
11 (57.9)
3 (15.8)
2 (28.6)
3 (42.8)
2 (28.6)
0.763 +
Surgery, n (%)
VATS
Open
Without surgery
3 (17.6)
4 (23.5)
12 (58.8)
0 (0.0)
1 (14.3)
6 (85.7)
0.144 +
Adjuvant therapy/palliative
treatment, n (%)
Chemotherapy
Immunotherapy
Chemotherapy and radiotherapy
Chemotherapy and immunotherapy
Immunotherapy and radiotherapy
Palliative treatment
6 (31.6)
1 (5.3)
7 (36.8)
2 (10.5)
2 (10.5)
1 (5.3)
2 (28.6)
1 (14.3)
4 (57.1)
0 (0.0)
0 (0.0)
0 (0.0)
0.385 +
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; TNM, tumor node metastasis;
VATS, video-assisted thoracic surgery; VES-13, Vulnerable Elders Survey-13. Data are reported as mean ± standard
deviation or number (%). Differences between groups were analysed using * U Mann Whitney for nominal data,
+ X2 test for nominal data, or † the Kruskal–Wallis test for ordinal data.
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3.2. Intervention Effects
Table 3 shows the results of physical functioning in both groups and the differences between
groups after the 10-week program. The IG showed a significant increase in the following functional
capacity tests: SPPB gait speed test 4-m (p = 0.008), chair stand test (p = 0.009), total score (p = 0.004),
and the 5-m GVT (p = 0.036). Additionally, the IG group showed significantly improved muscle
performance (strength) measured as leg press (p < 0.001), chest press (p < 0.001), and hip abduction
(p = 0.001). By contrast, there was a significant decrease in functional capacity in the CG: 5-m GVT
(p = 0.020), GVT verbal (p = 0.017), TUG (p = 0.016). Additionally, there was a significant decrease in
muscle performance in 1RM chest press (p = 0.049) and chest power (p = 0.022). A significant difference
was found in functional capacity between groups: SPPB gait speed test 4-m, chair stand test, total score
(p = 0.002); 5-m GVT (p = 0.005), GVT verbal (p = 0.006), GVT arithmetic (p = 0.012); TUG (p = 0.007);
and Barthel index (p = 0.044). There was a significant difference in muscle performance (strength) for
leg press (p < 0.001), chest press (p = 0.001), and flexion hip (p = 0.024).
Table 3. Results of physical functioning outcomes by group.
Intervention Group
(n = 19)
Control Group
(n = 7) Group Difference
∆ (95% CI)
p-Value Groups +
Before After p-Value * Before After p-Value *Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
Functional capacity
Gait Speed Test 4-m (s) 5.62 (1.57) 4.89 (1.19) 0.008 4.85 (0.83) 5.71 (0.87) 0.051 −1.60 (−2.55 to -0.65); 0.002
Static Balance (Score) 3.84 (0.37) 4.00 (0.00) 0.083 † 3.57 (1.13) 3.57 (0.79) 1.000 † 0.34 (0.25 to 0.43); 0.024
Chair Stand Test (s) 12.23 (3.37) 10.29 (2.39) 0.009 10.66 (1.47) 15.48 (7.83) 0.132 −6.75 (−10.80 to −2.70); 0.002
SPPB Total (Score) 9.84 (1.92) 10.95 (1.03) 0.004 10.86 (1.35) 9.43 (1.27) 0.118 2.53 (1.05 to 4.02); 0.002
GVT 5-m (s) 6.25 (1.63) 5.62 (1.38) 0.036 5.43 (1.09) 6.30 (0.69) 0.020 −1.49 (−2.49 to −0.49); 0.005
GVT Verbal (s) 6.63 (1.71) 6.47 (1.29) 0.657 5.30 (1.10) 7.22 (1.15) 0.017 −2.08 (−3.50 to −0.66); 0.006
GVT Arithmetic (s) 6.82 (1.88) 6.35 (1.51) 0.155 6.26 (1.24) 7.45 (1.52) 0.062 −1.66 (−2.91 to −0.41); 0.012
TUG (s) 12.01 (2.80) 11.03 (3.20) 0.097 11.39 (1.67) 13.37 (1.28) 0.016 −2.96 (−5.02 to −0.89); 0.007
6MWT (m) 414.69(120.79)
420.11
(101.77) 0.722
425.71
(71.52)
398.50
(65.15) 0.134 29.92 (−26.83 to 86.66); 0.286
Barthel Index (Score) 96.58 (5.79) 98.16 (4.15) 0.084 † 100.00(0.00) 97.86 (3.93) 0.180
† 0.05 (0.01 to 0.09); 0.044 ‡
Muscular performance
1RM Chest Press (kg) 43.89(13.77)
52.79
(17.16) <0.001 34.71 (8.22) 29.33 (5.89) 0.049 12.89 (5.60 to 20.19); 0.001
1RM Leg Press (kg) 100.74(35.45)
150.63
(47.06) <0.001
76.43
(25.30)
66.67
(14.46) 0.338 52.73 (38.03 to 67.42); <0.001
Chest Muscle Power (w) 99.00(48.30)
136.26
(57.56) <0.001
76.14
(34.58)
52.50
(19.61) 0.022 52.26 (25.67 to 78.86); <0.001
Leg muscle Power (w) 152.26(86.13)
262.42
(103.92) <0.001
108.14
(57.21)
72.83
(31.51) 0.071
134.16 (89,91 to 178.40);
<0.001 *
Hand Grip (kg) 34.58 (8.35) 34.16 (9.00) 0.618 28.00 (8.71) 28.29 (8.02) 0.811 −0.71 (-3.88 to 2.47); 0.650
Knee Extension (kg) 9.59 (1.76) 11.63 (3.01) 0.013 9.25 (1.76) 8.78 (2.25) 0.701 2.52 (−0.41 to 5.45); 0.089
Flexion Hip (kg) 9.31 (3.23) 10.40 (3.03) 0.044 9.03 (2.98) 7.45 (1.26) 0.244 2.67 (0.39 to 4.94); 0.024
Abduction Hip (kg) 8.05 (2.10) 9.68 (1.86) 0.001 6.55 (1.30) 6.78 (1.83) 0.769 1.39 (−0.24 to 3.02); 0.092
Abbreviations: SD: Standard deviation; SPPB: Short Physical Performance Battery; GVT: Gait Velocity Test; TUG:
Timed Up and Go; 6MWT: 6 Minute Walk Test; RM: Repetition maximum. * T test of related samples; + T test
of independent samples; † Wilcoxon; ‡ U Mann Whitney. The muscle power output in the propulsive phase was
recorded by connecting a velocity transducer to the eGym® machines (T-Force System, Ergotech, Murcia, Spain).
Table 4 shows the results of cognitive functioning within the two groups and the differences
between groups. The significant increase in MMSE observed in the IG (p=0.005) resulted in a significant
difference between groups (p = 0.021).
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Table 4. Results of cognitive functioning outcomes by group.
Intervention Group
(n = 19)
Control Group
(n = 7) Group Difference
∆ (95% CI)
p-Value Groups +
Before After p-Value * Before After p-Value *Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
MMSE (Score) 28.16 (1.07) 28.89 (0.81) 0.005 27.57 (2.82) 27.14 (1.95) 0.407 1.17 (0.19 to 2.14); 0.021
Verbal Fluency Test
(Score) 11.37 (5.84) 12.11 (5.36) 0.380 9.43 (5.47) 7.57 (5.38) 0.191 2.59 (−0.61 to 5.80); 0.108
TMT-A (s) 68.32(38.96)
65.92
(47.34) 0.676
86.10
(62.19)
78.35
(44.36) 0.505 5.34 (−18.17 to 28.86); 0.643
Abbreviations: SD: Standard deviation; MMSE: Mini-mental state examination; TMT-A: Trail making test part A. * T
test of related samples; + T test of independent samples.
Table 5 shows the results of HRQoL domains within and between both groups. The CG did
not show major differences, whereas the IG showed a significant improvement in the EUROQoL 5D
questionnaire in total score (p = 0.038), EORTC QLQ-C30 questionnaire in physical function (p = 0.037)
and global health status/quality of life (p = 0.029), and a significant decrease in pain symptoms
(p = 0.030) and dyspnea (p = 0.025), as well as pain in other body parts (p = 0.025) in the EORTC
QLQ-LC13 questionnaire. The significant difference between groups was found for EUROQoL 5D
questionnaire in total score (p = 0.006), and pain in other body parts (p = 0.007).
Table 5. Results of health-related quality of life domains by group.
Intervention Group
(n = 19)
Control Group
(n = 7) Group Difference
∆ (95% CI)
p-Value Groups +
Before After p-Value * Before After p-Value *Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
EUROQoL 5D
EUROQoL 5D a 6.42 (1.35) 5.74 (1.19) 0.038 5.14 (0.38) 6.14 (1.21) 0.038 −1.68 (−2.83 to -0.53); 0.006
EUROQoL 5D Health b
69.05
(12.51)
73.26
(17.53) 0.340
72.29
(21.73)
72.14
(17.76) 0.974 4.35 (−11.28 to 19.99); 0.571
EORTC QLQ-C30 (Functioning scale b)
Physical 72.20(26.70)
83.30
(20.90) 0.037
88.60
(15.70)
82.90
(18.00) 0.172
† 16.83 (−0.31 to 33.96); 0.054
Role 88.90(32.30)
97.20
(11.80) 0.276
† 100.00
(0.00)
100.00
(0.00) 1.000 0.90 (0.84 to 0.96); 0.707
‡
Cognitive 80.60(25.10)
86.10
(20.00) 0.163
92.90
(18.90) 95.20 (8.10) 0.788
† 3.17 (−13.42 to 19.77); 0.696
Emotional 80.10(19.80)
82.40
(18.10) 0.686
85.70
(13.40)
85.70
(19.70) 1.000
† 2.31 (−17.91 to 22.54); 0.815
Social 80.60(25.70)
86.10
(20.80) 0.397
† 100.00
(0.00)
81.00
(27.90) 0.109 0.05 (0.01 to 0.09); 0.062
‡
Global Health status/QoL b
64.80
(21.30)
76.90
(11.60) 0.029
† 77.40
(17.20)
72.60
(14.20) 0.436
† 16.80 (−1.61 to 35.21); 0.072
EORTC QLQ-C30 (Symptom scales and/or items c)
Fatigue 35.80(29.40)
30.20
(21.80) 0.464
14.30
(15.30)
14.30
(15.30) 1.000
† −5.56 (−21.83 to 10.72); 0.485
Nausea and Vomiting 8.30 (24.40) 3.70 (10.80) 0.655 † 0.00 (0.00) 2.40 (6.30) 0.317 0.56 (0.46 to 0.66); 0.362 ‡
Pain 32.40(32.60)
14.80
(21.30) 0.030
14.30
(26.20)
26.20
(30.20) 0.454
† −29.50 (−60.61 to 1.61); 0.062
Dyspnea 13.00(20.30) 3.70 (10.80) 0.025
† 14.30
(26.20) 0.00 (0.00) 0.180 0.67 (0.58 to 0.76); 0.817
‡
Sleep Disturbance 29.60(36.00)
22.20
(34.30) 0.506
† 14.30
(26.20)
14.30
(26.20) 1.000 0.88 (0.82 to 0.94); 0.818
‡
Appetite Loss 25.90(33.40)
13.00
(28.30) 0.083
† 14.30
(26.20)
19.00
(37.80) 0.655 0.39 (0.29 to 0.49); 0.364
‡
Constipation 22.20(30.20)
13.00
(23.30) 0.248
† 23.80
(31.70)
33.30
(47.10) 0.577 0.20 (0.12 to 0.28); 0.185
‡
Diarrhea 13.00(28.30)
18.50
(28.50) 0.603
† 0.00 (0.00) 9.50 (16.30) 0.157 0.92 (0.87 to 0.97); 0.804 ‡
Financial Impact 0.00 (0.00) 0.00 (0.00) 1.000 † 4.80 (12.60) 0.00 (0.00) 0.317 0.32 (0.23 to 0.41); 0.109 ‡
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Table 5. Cont.
Intervention Group
(n = 19)
Control Group
(n = 7) Group Difference
∆ (95% CI)
p-Value Groups +
Before After p-Value * Before After p-Value *Mean
(SD)
Mean
(SD)
Mean
(SD)
Mean
(SD)
EORTC QLQ- LC13 c
Coughing 38.90(23.60)
24.10
(25.10) 0.104
28.60
(12.60)
23.80
(16.30) 0.356
† −10.05 (−30.42 to 10.32); 0.318
Hemoptysis 0.00 (0.00) 0.00 (0.00) 1.000 † 4.80 (12.60) 0.00 (0.00) 0.317 0.32 (0.23 to 0.41); 0.109 ‡
Dyspnoea 14.20(15.60)
14.20
(14.70) 1.000
12.70
(20.70)
12.70
(16.30) 1.000
† 0.00 (−11.30 to 11.30); 1.000
Sore Mouth 9.30 (22.30) 14.80(28.50) 0.546
† 0.00 (0.00) 4.80 (12.60) 0.317 0.98 (0.95 to 1,00); 0.826 ‡
Dysphagia 9.30 (22.30) 7.40 (18.30) 0.705 † 0.00 (0.00) 4.80 (12.60) 0.317 0.40 (0.30 to 0.50); 0.225 ‡
Peripheral Neuropathy 9.30 (19.20) 13.00(23.30) 0.414
† 9.50 (25.20) 0.00 (0.00) 0.317 0.18 (0.11 to 0.26); 0.250 ‡
Alopecia 5.60 (17.10) 11.10(22.90) 0.408
† 0.00 (0.00) 19.00(37.80) 0.180 0.45 (0.35 to 0.55); 0.540
‡
Pain in Chest 13.00(20.30) 9.30 (15.40) 0.317
† 14.30
(17.80) 4.80 (12.60) 0.157 0.59 (0.49 to 0.69); 0.416
‡
Pain in Arms or Shoulder 13.00(30.50) 7.40 (21.60) 0.414
† 4.80 (12.60) 0.00 (0.00) 0.317 1.00 (0.97 to 1.00); 0.705 ‡
Pain in Other Body Parts 31.50(35.20) 9.30 (19.20) 0.025
† 14.30
(26.20)
42.90
(46.00) 0.059 0.00 (0.00 to 0.03); 0.007
‡
Categorical Pain Scale d 1.89 (2.35) 1.16 (2.34) 0.317 † 0.57 (1.51) 1.14 (1.95) 0.564 † 0.25 (0.17 to 0.34); 0.216 ‡
GDS e 2.79 (1.72) 2.74 (2.66) 0.917 1.57 (1.51) 2.71 (1.80) 0.103 −1.20 (−3.06 to 0.67); 0.197
Borg Scale d 3.67 (0.91) 4.00 (1.33) 0.210 3.14 (0.38) 3.00 (1.67) 1.000 0.33 (−0.88 to 1.55); 0.575
Abbreviations: SD: Standard deviation; EUROQoL 5D: European Quality of Life-5 Dimensions; EORTC: European
organization for research and treatment of cancer quality life questionnaire; QoL: quality of life; GDS: Geriatric
depression scale; * T test of related samples; + T test of independent samples. † Wilcoxon; ‡ U Mann Whitney. a The
scores range from 5 to 15, with a lower score that represents a better QoL; b The scores range from 0 to 100, with a
higher score representing a higher level of functioning; c Symptoms and side effects scales and items, scores ranging
from 0 to 100, with a higher score representing a higher level of symptoms and side effects; d The scores range from
0 to 10, the lowest score means no pain or perceived exertion; e The score shows, normal 0–5, probable depression
6–9, established depression >9 points.
4. Discussion
Supervised exercise training can be beneficial for patients with lung cancer by increasing functional
capacity, exercise tolerance, and physical performance/fitness, and by reducing emotional distress.
Our findings confirm our hypothesis that a multicomponent exercise program in the elderly with
NSCLC under adjuvant therapy or palliative treatment positively affects measures of functional
capacity measured by SPPB, GVT, and muscular performance (1RM and power). Our results also
suggest that such an intervention improves cognitive functioning (MMSE score) and quality of life
(physical function, pain symptoms, and dyspnea). We believe that the present study represents an
important addition to the current body of knowledge on the safety of exercise interventions, particularly
in the elderly with NSCLC under adjuvant therapy or palliative treatment.
The safety, benefits, and application of a multicomponent program in patients with lung cancer
with the goal of improving physical and mental outcomes have been previously established [10].
Rosero et al. [13] reported a strong negative relationship between exercise capacity, including
sub-maximal oxygen consumption, and several emotional issues (quality of life, depression and
fatigue) and medical care (days of hospitalization and postoperative complications) in patients with
NSCLC. In our study, we found differences in physical performance between groups (post-pre change
2.53; 95% CI 1.05 to 4.02) measured by the SPPB, despite the aggressive nature of the disease and its
treatment. Previous studies have reported that impaired mobility is reflected by total SPPB scores
of less than 10, and those patients with total SPPB scores of 7–9 are 1.6 to 1.8 times more likely to
become disabled [33,34]. The 6MWT is one of the most common measures in studies on lung cancer
and exercise. In the present study, the minimum significant difference in individuals with lung cancer
(22–42 m) was not achieved, although there was an increase of 5.4 m on average between initial and
final evaluation in the IG, compared with a decrease of 27.2 m in the CG. Similarly, Dhillon et al. [35]
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reported an increase in 6MWT from baseline to post-intervention in the exercise group (234.9 m to
516.3 m) as well as the control group (251.0 m to 517.7 m), but there was no significant between-group
difference (p = 0.972).
The improved function and metabolism of skeletal muscle is likely to explain the improvements in
functional capacity, including the 4- and 5-m walk tests, getting up from a chair, total SPPB score, and
muscle performance. Similarly, skeletal muscle function improves significantly after a multicomponent
exercise program in older adults [24]. Loss of skeletal muscle function results in reduced physical
performance during sub-maximal exercise as well as a reduced capacity to oxidize fats as a fuel, and
this is in part due to a reduction of muscle mitochondria in NSCLC patients.
In clinical studies on patients with lung cancer, several authors have reported cognitive deficits
early after following chemotherapy treatment, particularly on executive function, verbal fluency, and
verbal memory [36,37]. Whilst chronic exercise seems to improve memory, verbal concept formation,
selective attention, and conflict resolution, studies have focused mainly in older adults [35]. We found
a significant improvement in cognitive function by MMSE, a key component of the intrinsic capacity of
individuals that is a combination of all physical and mental abilities, which helps to preserve autonomy
and independence in essential daily activities [38].
Overall, the possible positive effects of chronic physical exercise on executive functions may
be explained by the improved structural connectivity of the prefrontal brain areas. It has been
shown that white matter integrity in the prefrontal cortex is important for executive functioning [39].
Among the different components of executive function, the present study focused on cognitive
inhibition and attention capacity. Mechanisms such as angiogenesis, synaptogenesis, and neurogenesis
have been proposed as possible mediating factors in the exercise-cognition relationship. Specifically,
several hypotheses may explain this relationship: i) regulation of neurotrophins (such as growth
factors, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5); ii) increases in
oxygen saturation due to increased blood flow and circulatory angiogenesis; and iii) increases in brain
neurotransmitters (e.g., norepinephrine and serotonin) facilitating information processing [40]. This is
likely to explain the association between exercise training and higher executive function.
Emerging evidence suggests that structured exercise can confer protection against the emergence
of mental illness and be used as an adjunctive treatment in several chronic diseases [41]. Moreover,
meta-analyses have demonstrated small but significant improvements in quality of life following exercise
training in cancer survivors [42,43]. Of note, these reviews of cancer survivors contained few participants
with advanced lung cancer [11]. With regard to quality of life, we found a significant improvement in
physical functioning, symptom levels (pain and dyspnea), and significant improvements in HRQoL in
those patients whose performance status had improved. Preliminary studies suggest that supervised
exercise and multicomponent programs may benefit mental health, with significant improvements
in reducing the severity of depression and anxiety in cancer survivors [44–47]. In the present study,
significant differences between groups were found only for pain in other body parts (p= 0.007). Using the
EORTC-QLQ-C30 questionnaire, Dhillon et al. [35] found no difference in HRQoL score (p = 0.817)
between the supervised exercise group (63.8 to 63.2) and the control group (58.9 to 64.3) on completion
of an eight-week intervention. In this respect, further research to determine the effects and optimal
dosage of exercise programs in this particular population is warranted.
In this study, differences were observed in the groups according to age. However, although age
is an important factor that has a significant impact on the quality of life and mortality in the elderly
population with lung cancer, this difference is relatively small, in part due to design of non-randomized
design trial and we were encouraged to reinforce our findings.
5. Limitations
Exercise is widely recommended to cancer patients. However, knowledge of the optimal parameters
of physical exercise (mode, intensity, frequency, duration, and time) is lacking for patients with NSCLC,
and so it is difficult for physicians to correctly prescribe physical exercise. Our study uses an exercise
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protocol that could be followed to obtain benefits on physical, cognitive functioning, and mental
well-being. It is also one of the few studies that assesses whether a supervised and individualized
physical intervention is beneficial and safe for patients with advanced NSCLC under adjuvant therapy
or palliative treatment. None of the previous studies that have evaluated physical training in older
adults with lung cancer reported serious adverse events [46–52], which is consistent with the findings
of our study.
This study has several limitations that should be considered before interpreting these findings.
Firstly, the number of participants in our study was relatively small, and so larger multicenter studies
are encouraged to reinforce our findings. A second limitation was the poor condition of three patients
in the CG that prevented the evaluation of the changes from the study beginning to end, which could
have revealed significant differences in other measurement variables. While there were no adverse
events, the sample may be below the number needed to show harm. These limitations are important
and should be addressed in the future.
6. Conclusions and Future Recommendations
In conclusion, patients with NSCLC have a clear indication of starting a multicomponent exercise
program during adjuvant therapy or palliative treatment for their disease. Our findings point to several
future directions for research. In general, the physical exercise intervention seems to provide physical,
cognitive, and emotional benefits in older adults with NSCLC under adjuvant therapy or palliative
treatment. Future studies should analyze the cellular benefits in this population, and also study the
correlation between physical exercise and the toxicity of cancer treatments. Well-designed randomized
clinical trials should be performed to corroborate the current findings with a larger sample size to
detect a significant difference in the components studied.
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